Wanbury Ltd has achieved strong net sales growth of 47 per cent during the quarter ended December 2008 and its sales touched to Rs 83.64 crore from Rs 56.91 crore in the corresponding period of last year. However, its net profit declined to Rs 3.68 crore from Rs 722 crore mainly due to foreign exchange loss of Rs 7.7 crore as against nil in the previous period.

The company's profit before interest, depreciation and taxation improved to Rs 10.99 crore from Rs 8.21 crore. The interest burden, which increased to Rs 5.06 crore from Rs 2.38 crore, has put additional burden on bottom line.

The company's net sales for the 18 months period ended September 2008 reached at Rs 388.47 crore and it earned a net profit of Rs 29.78 crore with EPs of Rs 20.54.

The company has fast growing presence in CRAMS catering to large MNCs globally for manufacturing their products. Wanbury has its sales office in Zurich, Switzerland and caters to US and European markets through its US FDA Plants. The company exports to over 70 countries, 65 per cent of which is to the regulated markets. Wanbury has two USFDA approved multi-product API facilities for regulated markets. The company has filed over 27 DMFs (Drug Master Files). Wanbury has pan India presence in ethical formulations with a portfolio of 52 brands.

Wanbury has presence in branded ethical finished dosage forms in Spain through Cantabria Pharma SL, its subsidiary. Cantabria Pharma SL, head quartered at Madrid, Spain, which employs over 100 people caters to key therapeutic areas like psychiatry, CNS, CVS, respiratory and pain management.